Brief: Lyell Immunopharma Announces The Initiation Of A Phase 3 Head-To-Head Car T-Cell Therapy Clinical Trial In Aggressive Large B-Cell Lymphoma And Formation Of Expert Steering Committee
03/09/2025 15:29
Lyell Immunopharma Inc LYEL.O: LYELL IMMUNOPHARMA ANNOUNCES THE INITIATION OF A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA AND FORMATION OF EXPERT STEERING COMMITTEE Source text: ID:nGNX1G2Rmq Further company coverage: LYEL.O
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma